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structural damage representing need for replacement hip/knee
arthroplasty) is a step forward, but analogous measures are needed for
other OA-affected joint regions like spine and hand.
The process of deﬁning a biomarker's usefulness may be summarized
conceptually in laboratory assay performance (analytical validation),
reviewing correlation with clinical outcomes or therapeutic response
(qualiﬁcation), and deﬁning a real-life context inwhich the biomarker is
useful (utilization). For example, LDL cholesterol has high analytical
validity and extensive evidence supporting its role in atherogenesis, is
utilized in risk prediction for cardiovascular disease, and even can be
used as a surrogate endpoint for cardiovascular events with statin
interventions. Imagine then a future OA biomarker that is analytically
valid when measured in blood or urine (or even synovial ﬂuid), has
extensive relationship to cartilage repair or regeneration or pain, and
predicts risk for later development of virtual joint replacement. Imagine
as well that a future intervention will change this biomarker's levels in
a manner that correlates with and captures reduced risk for virtual joint
replacement. That is where we want to be. Yet howwill we know when
we get there?
 We ask, “Can we measure it well enough?”When an OA biomarker
can be reliably measured, we'll see publications showing little
extraneous variation and agreement among various assays and
laboratories with deﬁned international standards.
 We ask, “Does it connect rationally to the OA features we see?”
When an OA biomarker is connected reproducibly to disease
outcome and possibly intervention, we'll see abundant evidence
that a biomarker lies along a known pathogenetic pathway within
a deﬁned biological model (such as by Bradford Hill criteria),
correlates with symptoms or function or structural alteration, and
maybe captures response to an intervention.
 We ask, “How should it be used?” When an OA biomarker applies
to a speciﬁc proposed use, we'll see epidemiological studies
showing an important and clinically useful context for the
biomarker use, such as in prevention, diagnosis, treatment, or
mitigation.
Thus, with the fruits of genomic approaches to ﬁnd genes that lie along
OA pathogenetic pathways and of experimental biology studies to
deﬁne how variants confer risk, we can expect to identify biomarker
candidates to be characterized as potential OA biomarkers.
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THE RELEVANCE OF THE HUPO HUMAN PROTEOME PROJECT FOR
PROTEOMICS STUDIES OF OSTEOARTHRITIS
G.S. Omenn. Univ. of Michigan, Ann Arbor, MI
Purpose: To identify and characterize at least one protein from each of
the 20,300 human protein-coding genes. See Legrain et al., Mol. Cell
Proteomics (2011). To facilitate disease-related biomarker development.
Methods: Global collaborative Human Proteome Project (HPP), orga-
nized by the Human Proteome Organization (HUPO). Use of Proteo-
meXchange, linking data repositories EBI-PRIDE and neXtprot, ﬁle
sharing system Tranche, mass spectrometry-based Peptide Atlas and
SRM Atlas, and Ab-based Human Protein Atlas, to share data, reanalyze
mass spectrometry ﬁndings with a rigorous, standardized protocol, and
lay the foundation for protein biomarkers of health and disease.
Results: The Human Proteome Project was announced at the HUPO
World Congress in Sydney, Australia, in September 2010 and launched at
the HUPO World Congress in Geneva, Switzerland, in September 2011.
The HPP draws upon resource pillars for mass spectrometry, protein
capture, and knowledge base. There is some degree of evidence at the
protein level for about 13,000 of the 20,300 proteins. The HPP has two
large collaborative components: the chromosome-centric C-HPP, with so
far 16 national or international research teams characterizing the
proteins coded by genes on one chromosome each; and the biology and
disease-driven B/D-HPP, which has embraced the pre-existing organ-
based and bioﬂuid-based proteome projects of the past decade under the
aegis of HUPO. For example, the chromosome 17 team is annotating the
1182 proteins coded by genes on this chromosome (based on Ensembl,
SwissProt, and neXtprot), with a disease focus on breast cancer, reﬂecting
the breast cancer-associated Chr 17 genes ERBB2 (Her2), BRCA1, p53, and
GRB7. We are determining the concordance of protein identiﬁcations by
immunohistochemistry and by mass spectrometry and the tissueexpression patterns for the canonical proteins and for splice variants and
various types of post-translational modiﬁcations. Information about the
HPP is available at http://thehpp.org.
Conclusions: The combined chromosome-centric and biology and
disease-driven Human Proteome Project efforts are becoming well-
organized. The HPP will add greatly to our conﬁdent identiﬁcation of
human proteins currently not yet identiﬁed or mapped for tissue and
subcellular expression. The HPP provides a foundation for interpreting
results of proteomic biomarker studies of osteoarthritis and integrating
proteomics data with other omics platforms to relate genotype to
phenotype (Figure 1).
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SURGICAL MANAGEMENT OF OSTEOARTHRITIS: OPTIONS AND
OUTCOMES
J.N. Katz. Brigham and Women's Hosp., Boston, MA
Purpose: To review the options and outcomes of surgical management
of osteoarthritis of the knee and hip.
Methods: Review of pertinent peer reviewed literature.
Results: Arthroscopic lavage and debridement are no more efﬁcacious
than sham surgery or physical therapy in the management of osteoar-
thritis of the knee. The efﬁcacy of arthroscopic partial meniscectomy in
the management of meniscal tear in the setting of knee ostearthritis is
uncertain and requires further study. There has been little rigorous
comparison of osteotomy or unicompartmental knee arthroplasty with
nonoperative treatments for knee OA. Total joint arthroplasty is an
effective and cost effective intervention for advanced knee or hip
osteoarthritis. The utilization of total knee arthroplasty has expanded
considerably into younger and older populations, particularly patients
<65 years old. The outcomes of TKA in this population requires careful
study. New surgical approaches, devices and biomaterials are intro-
duced routinely in an effort to improve outcomes of total joint arth-
plasty. These innovations must be scrutinized carefully before
widespread adoption in order to ensure that they improve upon the
excellent short and long term outcomes achieved with existing
technology.
Conclusions:Whilecontinued research isneededurgently to optimzeuse
of these costly interventions, a growing body of evidence permits judi-
cious use of surgical interventions for osteoarthritis of the hip and knee.
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TECHNICAL DEVELOPMENTS IN GENETIC MODIFIED ANIMAL MODEL
P.M. van der Kraan. Radboud Univ., Med. Ctr., Nijmegen, Netherlands
Animal models are until now irreplaceable tools of osteoarthritis
research. Studies can make use of either spontaneous occurring oste-
oarthritis or of induced models to study the disease process. However,
the role of speciﬁc genes and proteins in osteoarthritis has made a big
step forward after the generation of transgenic animal models, mainly
in the mouse. The generation of transgenic animal models has shown
a vast development in the years since the ﬁrst transgenic mouse was
created bymicro-injection and random integration of DNA. The creation
of knock out mice, the use of tissue speciﬁc promoters, ﬂoxed mice, and
the introduction of inducible expression systems has advanced the
usability of these transgenic mice in OA research worldwide. This
workshop will focus on the latest developments in murine transgenics
and illustrate the contribution of these models to our understanding of
the OA disease process.
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BIOLOGICAL SURGICAL REPAIR
A.H. Gomoll. Brigham and Women's Hosp., Boston, MA
Articular cartilage defects are common, being encountered inmore than
half of all knee arthroscopies. While not all defects are symptomatic,
those that are can cause disability comparable to that seen in patients
awaiting knee replacement for advanced osteoarthritis. Knee replace-
ment provides good pain relief with relatively high patient satisfaction
over 70%, and 10 year survival rates of 80% to 90%. However, the
majority of these studies were conducted in older patients, ranging in
age from the late 60s to early 80s. Younger patients are less satisﬁed
with the outcome and also demonstrate higher implant failure rates. It
therefore appears reasonable to attempt delaying arthroplasty as long
as possible, especially in young patients.
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to consideration of surgical intervention. Young patients with large
defects present a potential exception to this recommendation, since
lesion growth can occur evenwith symptomatic improvement from non-
operative treatment, potentially worsening the structural problem. For
example, the majority of young patients experience almost complete
resolution of knee pain after removal of a loose osteochondritis dissecans
(OCD) fragment. However, if the defect is left empty, 50% to 80% will
develop radiographic evidence of osteoarthritis after 8 to10 years. This is
the patient population where cartilage repair is deemed most beneﬁcial,
in hopes of slowing the progression of degenerative changes.
Cartilage damage encompasses a wide spectrum ranging from focal
chondral defects all the way to tricompartmental osteoarthritis. While
the latter is beyond the capabilities of current cartilage repair proce-
dures, earlier stages in the disease process can be managed successfully
with cartilage repair. Historically, attempts at cartilage repair tended to
focus on the defect itself; often disregarding articular co-morbidities,
such asmalalignmentormeniscal deﬁciency, thatwere the root cause for
the development of cartilage damage in the ﬁrst place. Not surprisingly,
early reports of cartilage repairwere disappointing;more recent studies,
however, have shown success in over 70 to 80% of patients. This
substantial improvement has been attributed to the increased recogni-
tion and treatment of articular co-morbidities concurrently with carti-
lage repair in a process termed biologic joint reconstruction.
Cartilage repair options are chosen depending on defect location and
size. Generally, smaller defects (<2–3 cm2) are amendable to minimally
invasive procedures such as marrow stimulation and osteochondral
autograft transfer (also known as OATS or Mosaicplasty). Larger defects
have demonstrated disappointing outcomes with these procedures, and
are therefore mostly treated with cell-based therapy utilizing autolo-
gous chondrocytes or osteochondral allograft transplantation. Several
new implants are currently under development, and synthetic plugs
have received increased attention in hopes of providing a cost-efﬁcient,
off-the shelf option.
However, careful attention is required to correctly identify and address
the frequently present co-morbidities involved in the degenerative
disease process, such as malalignment and meniscal deﬁciency. The
concurrent use of osteotomy and meniscal transplantation is common
and necessary to normalize the biomechanical environment.
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EPIGENETICS: MARKS FOR FUTURE OA RESEARCH?
D.A. Young, M.J. Barter, C. Bui. Newcastle Unversity, Newcastle upon Tyne,
United kingdom
Purpose: Osteoarthritis (OA) is a complex multifactorial disease.
Several studies have suggested or identiﬁed epigenetic events, which
include DNA methylation, histone modiﬁcations, and microRNAs, that
may play a role in OA progression and the gene expression changes
observed in diseased cartilage. Collectively epigenetic modiﬁcations
allow the cell to respond quickly to environmental changes and these
can be inherited during cell division. However, aberrant epigenetic
modiﬁcations are associated with a number of pathological conditions,
including OA. The aim of this talk is to inform about current research in
epigenetics and epigenetics in OA. DNA methylation and chromatin
changes in OA are currently understudied, with most work focussing on
microRNAs which clearly have a role in skeletal development. Recent
advancements in epigenetic research suggest that global analysis of
suchmodiﬁcations in OA are now possible, however, with the exception
of microRNAs, it will be a signiﬁcant challenge to demonstrate how such
modiﬁcations impact on the disease or how they could be readdressed
to limit disease progression.
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OSTEOARTHRITIS IS AN INFLAMMATORY DISEASE
F. Berenbaum, Sr.1,2. 1 Pierre & Marie Curie Univ., paris, France; 2AP-HP
Saint-Antoine Hosp., Paris, France
Osteoarthritis (OA) has long been considered as a “tear-and-wear”
process. In the last 15 years, the face of OA has deeply changed, now
considered as a disease involving all tissues of a joint eventually leading
to cartilage degradation. Among these tissues, a particular attention has
been recently paid on the role of synovium in the OA process. A patchy
inﬂammation of this tissue is described, with some kind of correlation
between the degree of the synovitis and the prognostic of the disease.Whether this synovitis is a primummovens of the process or secondary
to a reaction to cartilage fragments falling into the joint remains
debated. Many inﬂammatory mediators belonging to the cytokine
family, to inﬂammatory lipid mediators, or to matrix components play
a critical role in the OA process. Interestingly, the source of these soluble
mediators may be the chondrocytes themselves (via autocrine/para-
crine loops), the synovial cells and the subchondral bone cells. Inter-
estingly, all the risk factors playing a role in OA have a potential to
increase the release of inﬂammatory mediators into the joints (adipo-
kines for obesity/metabolic syndrome, secretory proﬁle of senescent
chondrocytes, synovitis in post-trauma). The most recent studies
highlight the possibility of cross-talks between joint cells leading to
communication of mediators within and between the tissues of a joint.
Finally, the paradigm based on a mechanical-driven origin of the
disease is not conﬂictual with the inﬂammatory hypothesis since
mechanical signals are shifted into biochemical signals in chondrocytes
and subchondral bone cells via mechanoreceptors leading to the release
of pro-degradative and pro-inﬂammatory mediators.
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CHALLENGES IN STUDYING RISK FACTORS FOR OA PROGRESSION
Y. Zhang. Boston Univ., Boston, MA
Purpose: While several risk factors have been indentiﬁed for incident
radiographic knee osteoarthritis (ROA), ﬁndings on risk factors, espe-
cially chronic ones, for progression of ROA have been inconclusive. Some
factors that increase the risk of incident kneeROAhavean opposite effect
on ROA progression. The reasons for such a paradoxical phenomenon
have not been scrutinized. We explored several explanations that may
underlie thediscrepancybetweenﬁndings for kneeROAprogression and
those for knee ROA incidence using causal diagrams and real data, when
available. First, in observational studies of knee ROA progression
conditioning on (or limiting to) subjects who already have mild or
moderate disease will block the causal pathway between the risk factor
of interest, which often occurs prior to the occurrence of ROA, and ROA
progression; consequently it completely eliminates the effect of the risk
factor on OA progression. Second, conditioning on preexisting disease
will likely induce a negative correlation between the factor of interest
and potential confounders; such bias tends to dilute effect estimates.
Third, most studies of ROA progression often have followed participants
over a long period of time. If a substantial proportion of subjects are lost
to follow-up, the resulting selection bias can alter the effect estimate.
Finally, knees that progress toend stageduring the long interval between
imaging assessments will be treated the same at the end of the study
regardless of when they reached that stage; thus, the ceiling effects and
the relatively insensitive measures used to assess ROA progression will
make the effect estimate close to the null value. In conclusion, meth-
odological challenges in observational studies of risk factors for ROA
progression, especially chronic factors, are difﬁcult to overcome. Novel
study design and analytic approaches for ROA progression are required
to address these issues.
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WHAT MAKES CHONDROCYTES SPECIAL?
T. Hardingham. Univ. of Manchester, Manchester, United kingdom
Cartilage consists of a dense network of collagen ﬁbres embedded in an
aggrecan gel, within which is a sparse population of cells, the chon-
drocytes. Cartilage is tough and resilient and the matrix is dense and
does not allow migration or trafﬁcking of cells. The collagen and
aggrecan are of extremely slow turnover and the load bearing proper-
ties of cartilage depend on its physical integrity and cohesive structure.
Chondrocytes thus live within a special environment, which they are
responsible for assembling during development and maintaining
throughout life. Chondrocytes in adult cartilage thus lead a lonely
existence over many decades and the ageing of chondrocytes may be
a signiﬁcant factor in chondrocyte biology and pathology.
Cartilage chondrocytes are needed throughout life to make, repair and
remodel matrix. To carry out this function chondrocyte respond to
a whole range of physical and biochemical signals that guide the
balance of their activities. This includes paracrine and autocrine effects
of growth factors, cytokines and chemokines and the biomechanical
signals from tensile and compressive loading acting through cell matrix
interactions and accompanying ionic and osmotic ﬂuxes. These
processes require the co-ordinated activity of many different pathways
